110 related articles for article (PubMed ID: 25742233)
21. 18F-DOPA PET/CT biodistribution consideration in 107 consecutive patients with neuroendocrine tumours.
Chondrogiannis S; Grassetto G; Marzola MC; Rampin L; Massaro A; Bellan E; Ferretti A; Mazza A; Al-Nahhas A; Rubello D
Nucl Med Commun; 2012 Feb; 33(2):179-84. PubMed ID: 22083098
[TBL] [Abstract][Full Text] [Related]
22. Hyperaccumulation of (18)F-FDG in order to differentiate solid pseudopapillary tumors from adenocarcinomas and from neuroendocrine pancreatic tumors and review of the literature.
Guan ZW; Xu BX; Wang RM; Sun L; Tian JH
Hell J Nucl Med; 2013; 16(2):97-102. PubMed ID: 23687644
[TBL] [Abstract][Full Text] [Related]
23. 18F-DOPA and other radiopharmaceuticals for imaging unknown primary neuroendocrine tumors.
Schillaci O
J Nucl Med; 2014 Mar; 55(3):357-9. PubMed ID: 24396031
[No Abstract] [Full Text] [Related]
24. 18F-DOPA PET/CT and neuroendocrine tumours.
Nanni C; Rubello D; Fanti S
Eur J Nucl Med Mol Imaging; 2006 May; 33(5):509-13. PubMed ID: 16912994
[No Abstract] [Full Text] [Related]
25. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas.
Imani F; Agopian VG; Auerbach MS; Walter MA; Imani F; Benz MR; Dumont RA; Lai CK; Czernin JG; Yeh MW
J Nucl Med; 2009 Apr; 50(4):513-9. PubMed ID: 19289420
[TBL] [Abstract][Full Text] [Related]
26. Impact of residual (18)F-fluoride in (18)F-FDOPA for the diagnosis of neuroblastoma.
Huang YY; Tzen KY; Liu YL; Chiu CH; Tsai CL; Wen HP; Tang KH; Liu CC; Shiue CY
Ann Nucl Med; 2015 Jul; 29(6):489-98. PubMed ID: 25851249
[TBL] [Abstract][Full Text] [Related]
27. Dynamic 18F-FDOPA PET Findings After Carbidopa Premedication in 2 Adult Patients With Insulinoma-Related Hyperinsulinemic Hypoglycemia.
Imperiale A; Bahougne T; Goichot B; Bachellier P; Taïeb D; Namer IJ
Clin Nucl Med; 2015 Aug; 40(8):682-4. PubMed ID: 25549347
[TBL] [Abstract][Full Text] [Related]
28. Can (18)F-FDOPA PET/CT predict survival in patients with suspected recurrent glioma? A prospective study.
Karunanithi S; Sharma P; Kumar A; Gupta DK; Khangembam BC; Ballal S; Kumar R; Kumar R; Bal C
Eur J Radiol; 2014 Jan; 83(1):219-25. PubMed ID: 24191944
[TBL] [Abstract][Full Text] [Related]
29. The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors.
Kauhanen S; Seppänen M; Ovaska J; Minn H; Bergman J; Korsoff P; Salmela P; Saltevo J; Sane T; Välimäki M; Nuutila P
Endocr Relat Cancer; 2009 Mar; 16(1):255-65. PubMed ID: 19088184
[TBL] [Abstract][Full Text] [Related]
30. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression.
Fottner C; Helisch A; Anlauf M; Rossmann H; Musholt TJ; Kreft A; Schadmand-Fischer S; Bartenstein P; Lackner KJ; Klöppel G; Schreckenberger M; Weber MM
J Clin Endocrinol Metab; 2010 Jun; 95(6):2800-10. PubMed ID: 20371665
[TBL] [Abstract][Full Text] [Related]
31. (18)F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment.
Lizarraga KJ; Allen-Auerbach M; Czernin J; DeSalles AA; Yong WH; Phelps ME; Chen W
J Nucl Med; 2014 Jan; 55(1):30-6. PubMed ID: 24167081
[TBL] [Abstract][Full Text] [Related]
32. 18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience.
Ledezma CJ; Chen W; Sai V; Freitas B; Cloughesy T; Czernin J; Pope W
Eur J Radiol; 2009 Aug; 71(2):242-8. PubMed ID: 18511228
[TBL] [Abstract][Full Text] [Related]
33. Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas.
Tripathi M; Sharma R; D'Souza M; Jaimini A; Panwar P; Varshney R; Datta A; Kumar N; Garg G; Singh D; Grover RK; Mishra AK; Mondal A
Clin Nucl Med; 2009 Dec; 34(12):878-83. PubMed ID: 20139821
[TBL] [Abstract][Full Text] [Related]
34. Best sensitivity of
Testart Dardel N; Montravers F; Triviño-Ibañez E; Gauthé M; Houry S; Talbot JN
Rev Esp Med Nucl Imagen Mol; 2016; 35(6):402-405. PubMed ID: 27246293
[TBL] [Abstract][Full Text] [Related]
35. Manipulation of [11C]-5-hydroxytryptophan and 6-[18F]fluoro-3,4-dihydroxy-L-phenylalanine accumulation in neuroendocrine tumor cells.
Neels OC; Koopmans KP; Jager PL; Vercauteren L; van Waarde A; Doorduin J; Timmer-Bosscha H; Brouwers AH; de Vries EG; Dierckx RA; Kema IP; Elsinga PH
Cancer Res; 2008 Sep; 68(17):7183-90. PubMed ID: 18757434
[TBL] [Abstract][Full Text] [Related]
36. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess.
Fiebrich HB; Brouwers AH; Kerstens MN; Pijl ME; Kema IP; de Jong JR; Jager PL; Elsinga PH; Dierckx RA; van der Wal JE; Sluiter WJ; de Vries EG; Links TP
J Clin Endocrinol Metab; 2009 Oct; 94(10):3922-30. PubMed ID: 19622618
[TBL] [Abstract][Full Text] [Related]
37. Prospective comparison of (99m)Tc-GH SPECT/CT and (18)F-FDOPA PET/CT for detection of recurrent glioma: a pilot study.
Karunanithi S; Bandopadhyaya GP; Sharma P; Kumar A; Singla S; Malhotra A; Gupta DK; Bal C
Clin Nucl Med; 2014 Feb; 39(2):e121-8. PubMed ID: 23579970
[TBL] [Abstract][Full Text] [Related]
38. Impact of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/CT on managing patients with brain tumors: the referring physician's perspective.
Walter F; Cloughesy T; Walter MA; Lai A; Nghiemphu P; Wagle N; Fueger B; Satyamurthy N; Phelps ME; Czernin J
J Nucl Med; 2012 Mar; 53(3):393-8. PubMed ID: 22323780
[TBL] [Abstract][Full Text] [Related]
39. In vivo biodistribution of no-carrier-added 6-18F-fluoro-3,4-dihydroxy-L-phenylalanine (18F-DOPA), produced by a new nucleophilic substitution approach, compared with carrier-added 18F-DOPA, prepared by conventional electrophilic substitution.
Kuik WJ; Kema IP; Brouwers AH; Zijlma R; Neumann KD; Dierckx RA; DiMagno SG; Elsinga PH
J Nucl Med; 2015 Jan; 56(1):106-12. PubMed ID: 25500826
[TBL] [Abstract][Full Text] [Related]
40. (18)F-DOPA PET/CT and MRI: description of 12 histologically-verified pheochromocytomas.
Magnaldi S; Mayerhoefer ME; Khameneh A; Schuetz M; Javor D; Mitterhauser M; Dudczak R; Hacker M; Karanikas G
Anticancer Res; 2014 Feb; 34(2):791-5. PubMed ID: 24511014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
